Deuterated or partially deuterated N,N-dimethyltryptamine compounds
The present invention relates to compounds of formula (I) as defined herein, which comprise a greater proportion of deuterium to protium than naturally found in hydrogen; and compositions, including pharmaceutical compositions, comprising these compounds and optionally analogous compounds of formula (I), which are not deuterium-enriched. These compounds and compositions are of use in therapy, in particular in the treatment of psychiatric or neurological disorders. Varying the amounts of the different compounds within the compositions of the invention allows tailoring of the compositions' therapeutic effects. A particularly efficient synthetic method which enables compounds of formula (I) and related compounds of formula (I′) is also provided.
1. A compound of formula (I):
wherein:
R 1 is independently selected from —R 4 , —OH, —OR 4 , —O(CO)R 4 , monohydrogen phosphate, —F, —Cl, —Br and —I;
n is 0;
R 2 is CD 3 ;
R 3 is CD 3 or H;
each R 4 is independently selected from C 1 -C 4 alkyl; and
each y H is independently protium or deuterium,
or a pharmaceutically acceptable salt thereof,
wherein the compound of formula (I) is not the free base of N,N-di(trideuteromethyl)tryptamine, or N-mono(trideuteromethyl)tryptamine (also known as N-methyl-tryptamine-D 3 ).
2. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 4 is methyl.
3. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein both y H are deuterium or both y H are protium.
4. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein both R 2 and R 3 are CD 3 .
5. The compound of claim 1 , in the form of a pharmaceutically acceptable salt.
6. The compound of claim 1 , which is a pharmaceutically acceptable salt of N,N-di(trideuteromethyl)tryptamine or N-mono(trideuteromethyl)tryptamine (also known as N-methyl-tryptamine-D 3 .
7. The compound of claim 1 , wherein the pharmaceutically acceptable salt is a fumarate salt.
8. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein n is 0 and wherein the compound has a molecular weight from 188.9 to 196.3 grams per mole as the free base, or from 189.2 to 196.3 grams per mole as the free base, or from 194.3 to 196.3 grams per mole as the free base.
9. A composition comprising (a) a first compound, which is a compound or pharmaceutically acceptable salt thereof as defined in claim 1 , and (b) a second compound, which is either (i) a compound or pharmaceutically acceptable salt thereof as defined in claim 1 , but which differs from the first compound through the identity of y H and/or the identity of R 3 ; or (ii) a compound or pharmaceutically acceptable salt thereof as defined in claim 1 , except that each y H represents hydrogen.
10. A composition comprising a compound as defined in claim 1 , or a pharmaceutically acceptable salt thereof, in combination with a pharmaceutically acceptable excipient.
11. A method of psychedelic-assisted psychotherapy, comprising administering to a patient undergoing psychotherapy a therapeutically effective amount of a compound according to claim 1 , or a pharmaceutically acceptable salt thereof.
12. A method of treating a psychiatric or neurological disorder in a patient, comprising administering to the patient a therapeutically effective amount of a compound according to claim 1 , or a pharmaceutically acceptable salt thereof.
13. The method according to claim 12 , wherein the psychiatric or neurological disorder is selected from (i) an obsessive compulsive disorder, (ii) a depressive disorder, (iii) a schizophrenia disorder, (iv) a schizotypal disorder, (v) an anxiety disorder, (vi) substance abuse, and (vii) an avolition disorder.
14. The method according to claim 12 , wherein the disorder is major depressive disorder, or treatment resistant depression.
15. The method according to claim 12 , wherein said administering is oral administration of the compound or salt.